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Background
Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia
but their prognostic value is not well established.  
Design and Methods
We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated
with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent
trials of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) and
Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005.  
Results
FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%)
and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) patients had internal tan-
dem duplication and D835 mutations, respectively. Internal tandem duplication was correlated
with higher white blood cell and blast counts, lactate dehydrogenase, relapse-risk score, fever,
hemorrhage, coagulopathy, BCR3 isoform, M3 variant subtype, and expression of CD2, CD34,
human leukocyte antigen-DR, and CD11b surface antigens. The FLT3-D835 mutation was not
significantly associated with any clinical or biological characteristic. Univariate analysis
showed higher relapse and lower survival rates in patients with a FLT3-internal tandem dupli-
cation, while no impact was observed in relation to FLT3-D835. The prognostic value of the
FLT3-internal tandem duplication was not retained in the multivariate analysis.
Conclusions
FLT3-internal tandem duplication mutations are associated with several hematologic features
in acute promyelocytic leukemia, in particular with high white blood cell counts, but we were
unable to demonstrate an independent prognostic value in patients with acute promyelocytic
leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Key words: acute promyelocytic leukemia, FLT3mutations, prognostic factors, all-trans retinoic
acid, anthracyclines.
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Introduction
Constitutive activation of the fms-like tyrosine kinase 3
(FLT3) receptor due to internal tandem duplication (FLT3-
ITD) and a point mutation in the activation loop (FLT3-
D835) may confer proliferative and survival advantages to
acute myeloid leukemia blasts.1,2 The presence of FLT3
mutations, in particular of the ITD, has been consistently
associated with a worse outcome in patients with acute
myeloid leukemia with normal cytogenetics or intermedi-
ate-risk cytogenetics.3,4 However, the prognostic value of
FLT3 mutations in patients with acute promyelocytic
leukemia (APL), a form of acute myeloid leukemia charac-
terized by the specific t(15;17), is still a matter of contro-
versy. Although several studies in APL have reported an
association between FLT3-ITD and various characteristics,
including elevated white blood cell (WBC) count, BCR3
isoform, and microgranular morphology (M3v),5-15 the
prognostic value of these mutations remains to be estab-
lished. Two previous studies used multivariate analysis
including both WBC count, a well-known poor risk factor
in APL,16 and ITD in order to assess the independent value
of each one. The study by Gale et al.12 showed that the
WBC count was the sole independent prognostic factor
for relapse and survival. In contrast, Chillón et al.17 ana-
lyzed the prognostic value of the ratio and size of ITD and
found that both the length of the duplications and WBC
count were independent prognostic factors in APL. With
regards to the FLT3-D835 mutation, most authors were
unable to demonstrate that this mutation has an impact on
prognosis,7,9-11 although in some studies patients with the
D835 mutation were found to have worse outcomes.12,14
To provide new insights into the characterization of
FLT3 mutations in APL, we set out to evaluate the fre-
quencies of ITD and D835 mutations, as well as the size
and ratio of ITD, and their relationships with a broad vari-
ety of clinical and biological features. We also assessed the
prognostic value of these mutations in a large cohort of
APL patients enrolled in two successive trials of the
Programa de Estudio y Tratamiento de las Hemopatías Malignas
(PETHEMA) and Hemato-Oncologie voor Volwassenen
Nederland (HOVON) groups (LPA96 and LPA99).  
Design and Methods
Patients and eligibility
Between November 1996 and June 2005, 739 patients enrolled
in the consecutive multicenter PETHEMA LPA96 and PETHEMA/
HOVON LPA99 trials were required to have a diagnosis of de novo
APL with demonstration of the t(15;17) or PML/RARA rearrange-
ment. More details about the general exclusion and inclusion cri-
teria for these trials are reported elsewhere.18-20 According to the
Declaration of Helsinki, informed consent was obtained from all
patients, and the protocol was approved by the Research Ethics
Board of each participating hospital.
Therapy for acute promyelocytic leukemia
The induction regimen consisted of oral all-trans retinoic acid
(ATRA, 45 mg/m2/day) divided into two daily doses, which was
maintained until morphological complete remission was achieved,
and intravenous idarubicin (12 mg/m2/day) on days 2, 4, 6, and 8.
For patients 20 years of age or younger, the dose of ATRA was
adjusted to 25 mg/m2/day. From November 1999, the idarubicin
on day 8 was omitted for patients older than 70 years. Patients in
complete remission received three monthly consolidation courses.
The detailed consolidation schedule has been reported elsewhere.
Briefly, the first and the third courses consisted of idarubicin and
the second of mitoxantrone. From November 1999 (LPA99 study),
intermediate- and high-risk patients, as previously defined,21
received ATRA (45 mg/m2/day for 15 days) combined with the
three chemotherapy courses,19,20 and the idarubicin dose was
slightly increased. Patients who tested negative for PML/RARA at
the end of consolidation were started on maintenance therapy
with oral mercaptopurine, intramuscular methotrexate, and inter-
mittent oral ATRA over 2 years. Details of the supportive therapy
have been described elsewhere.18,22
Analysis of FLT3-ITD and FLT3-D835 mutations
Analyses for FLT3-ITD and FLT3-D835 mutations were per-
formed on bone marrow samples collected at the time the APL
had been diagnosed. Samples were sent to reference laboratories,
in sodium citrate or EDTA vials, and processed within 24 h. DNA
was obtained using QIAmp DNA Blood Mini Kit extraction kits
(QIAGEN GmbH Hilden, Germany) and UltraCleanTM extraction
kits (MO BIO Carlsbad, CA, USA). RNA was obtained using
Rneasy Mini kits (QIAGEN GmbH Hilden, Germany) or Trizol
reagent (Invitrogen Carlsbad, CA, USA). Then 0.5 µg of RNA were
reverse transcribed into cDNA in a 25 mL reaction volume with the
TaqMan Gold RT-PCR Kit (PE Applied Biosystems Branchburg,
NJ, USA). 
FLT3-ITD and FLT3-D835 mutations were studied qualitatively
in DNA or cDNA samples using the methods described by Nakao
et al.23 and Moreno et al.24 In selected cases, the presence of FLT3-
ITD and FLT3-D835 mutations was confirmed by sequencing the
amplified products. 
Quantitative assessment of FLT3-ITD mutations was performed
only in patients with available genomic DNA, by Genescan analy-
sis using a fluorescently labeled primer with 6-FAM to determine
the allelic FLT3-ITD ratio and size, following the method
described by Thiede et al.25 If several mutant alleles were detected
by Genescan, the mutant allele with the highest allelic ratio was
selected for the size analyses.
Definitions and study endpoints
Induction of remission was assessed according to the recently
revised criteria described by Cheson et al.26 For morphological
assessment of leukemia resistance, sufficient time had to have
passed to allow for full terminal differentiation of the malignant
promyelocytes (up to 40-50 days). Molecular remission was
defined as the disappearance on an ethidium bromide gel of the
PML/RARA-specific band visualized at diagnosis, using reverse
transcriptase polymerase chain reaction (RT-PCR) assays with a
sensitivity level of one cell in 10-4, or as the disappearance of the
PML/RARA rearrangement detected by real-time quantitative PCR
(RQ-PCR).27 Molecular persistence was defined as PCR positivity
in two consecutive bone marrow samples collected at the end of
consolidation therapy. The positive cases with a very low number
of copies (<5 copies) by RQ-PCR were confirmed to be positive
using a low sensitivity method (nested RT-PCR assay). Molecular
relapse was defined as the reappearance of PCR positivity in two
consecutive bone marrow samples at any time after consolidation
therapy.28 A genetic diagnosis of APL using PCR, anti-PML staining
or cytogenetic tests was required for the diagnosis of overt hema-
tologic relapse.
Differentiation syndrome was diagnosed and graded according
to previously defined criteria.29 Coagulopathy was defined as a
prolonged prothrombin time and/or activated partial thrombo-
plastin time in addition to hypofibrinogenemia and/or increased
levels of fibrin degradation products or D-dimers. Patients were
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classified as having t(15;17) with or without additional chromoso-
mal abnormalities in accordance with previously defined criteria.30
The patients’ performance status at diagnosis was measured using
the Eastern Cooperative Oncology Group (ECOG) scale. The risk
of relapse was estimated at diagnosis using a predictive model
based on the patients’ leukocyte and platelet counts at diagnosis,
as reported elsewhere.21 Relapse-risk groups were defined as
reported elsewhere19 and summarized here: low-risk patients had
a WBC count less than 10¥109/L and a platelet count more than
40¥109/L; intermediate-risk patients had a WBC count less than
10¥109/L and a platelet count less than 40¥109/L; and high-risk
patients had a WBC count of 10¥109/L of more.
Statistical methods
The χ2 test, with Yates’ correction if necessary, was used to ana-
lyze differences in the distribution of categorical variables
between subsets of patients. The Student’s t-test was used to ana-
lyze continuous variables with a normal distribution and Mann-
Whitney’s U test for data that failed the normality test. Thirty-four
characteristics of the patients and the disease were examined to
establish their relationship to FLT3-ITD and FLT3-D835 muta-
tions. These characteristics are listed in Tables 1 and 2. In addition
we analyzed the following variables: total body surface, levels of
serum creatinine, uric acid, albumin, total bilirubin, and fibrino-
gen, peripheral blood platelet count and hemoglobin levels, perox-
idase reactivity of bone marrow blasts, and CD9, CD13, CD33,
CD56 and CD117 surface antigen markers. For comparison, unad-
justed time-to-event analyses were performed using the Kaplan-
Meier estimate,31 log-rank tests and their generalizations.32 For all
estimates in which the event “relapse” was considered as an end-
point, hematologic and molecular relapse, as well as molecular
persistence (PML/RARA positive by RT-PCR at the end of consoli-
dation), were each considered as uncensored events. Overall sur-
vival was calculated from the time of diagnosis to the time of
death from any cause, and relapse-free survival from the date of
achieving complete remission to the time of relapse. All P values
reported are two-sided. The patients’ follow-up was updated on
March 15, 2010. The characteristics selected for inclusion in the
multivariate analysis, using the Cox proportional hazards model,
were those for which there was some indication of a significant
association in univariate analysis (P<0.1) and, if available, those for
which prior studies had suggested a possible relationship.
Computations were performed using the 4F, 3D, 1L and 2L pro-
grams from the BMDP statistical library (BMDP Statistical
Software Inc, Los Angeles, CA, USA).
Results
Incidence of FLT3 mutations
We were able to perform an analysis of FLT3-ITD muta-
tions at diagnosis in 306 (41%) patients (57 patients in the
LPA96 and 249 in the LPA99 trial), and FLT3-D835 in 213
(29%) of 739 patients with APL. The following character-
istics were observed more frequently in the patients tested
for FLT3 mutations than in those who were not tested
(n=433): LPA99 trial (P=0.01), fibrinogen concentration
less than 170 mg/dL (P= 0.04), and hemoglobin concentra-
tion less than 10 g/dL (P=0.06). The patients came from 53
institutions in Spain and The Netherlands (see Appendix),
and FLT3 analyses were routinely performed in eight ref-
erence laboratories (see Appendix). The median follow-up
of the series was 97 months (range, 15-158 months) from
diagnosis. 
Overall, 68/306 patients (22%) had a FLT3-ITD muta-
tion and 20/213 patients (9%) had a FLT3-D835. One
patient presented with both mutations concomitantly. 
Genescan analysis and sequencing of FLT3 mutations
Genescan analysis to determine size and ratio was con-
ducted in 39 patients with FLT3-ITD. The ratio of the
FLT3-ITD mutations ranged from 0.06 to 1.3 with a medi-
an of 0.66, and the length varied from 6 to 180 bp with a
median of 40 bp. Thirty-five patients showed only one
mutant allele, and four showed two mutant alleles of dif-
ferent sizes. 
Sequence analysis performed in 20 FLT3-ITD positive
and 10 FLT3-D835 positive APL samples showed that in all
cases ITD mutations consisted of in-frame duplications
involving exon 11, while D835 mutations consisted of
replacement of aspartic residue by tyrosine (8 cases) or
histidine (2 cases).
Patients’ characteristics according to FLT3 mutation status 
The main clinical and biological characteristics of the
patients according to FLT3 mutation status are summa-
rized in Tables 1 and 2. FLT3-ITD was significantly associ-
ated with higher WBC count, higher relapse-risk score,
more than 70% blasts in peripheral blood, BCR3 isoform,
M3v subtype (P<0.001 for all), lactate dehydrogenase lev-
els greater than 600 UI/L (P=0.005), presence of fever or
coagulopathy at diagnosis (both P=0.02), more than 70%
blasts in the bone marrow (P=0.03), and hemorrhage
(P=0.04). FLT3-ITD was also associated with expression of
the following surface markers: CD2, CD34 (both
P<0.001), HLA-DR (P=0.03), and CD11b (P=0.04)
By contrast, FLT3-D835 was not significantly associated
with higher WBC count or any other hematologic charac-
teristic (Table 2). 
Induction outcome
The overall induction death rate in the series was 8.8%.
As shown in Table 3, there was a significantly higher
induction death rate in patients with FLT3-ITD than in
patients without FLT3-ITD mutations (16% versus 7%,
P=0.03). The incidence of severe differentiation syndrome
was 22% among patients with FLT3-ITD mutations and
13% among those without FLT3-ITD (P=0.05).
Multivariate analysis identified a WBC count greater than
10×109/L (P<0.001), age greater than 60 years (P=0.001),
and creatinine levels greater than 1.4 mg/dL (P=0.02) as
independent prognostic factors for induction death. 
No significant associations were found with induction
outcomes according to the FLT3-D835 mutation status
(Table 4). 
Post-remission outcomes
Relapse-free survival
Fourteen relapses, 11 overt and 3 molecular, occurred
among the FLT3-ITD positive cohort at a median time of
16 months (range, 4-75 months) after achievement of
complete remission; and 27 relapses, 17 overt and 10
molecular, occurred among the FLT3-ITD negative cohort
at a median time of 23 months (range, 4-85 months) after
attainment of complete remission.
Univariate analysis showed a lower 5-year relapse-free
survival rate in FLT3-ITD-positive patients than in FLT3-
ITD-negative ones (77% versus 88%; P=0.02) and no
impact of FLT3-D835 mutation status (93% versus 84%;
P=0.29) (Figure 1 and Tables 3 and 4). We did not find sig-
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nificant differences in relapse-free survival according to
several levels of FLT3-ITD ratio (0.5, 0.66, and 0.8) or size
(40, 50, and 60 bp) (Table 3 and Figure 2). 
Multivariate analysis was performed including the fol-
lowing variables: age, gender, WBC count, relapse-risk
score, protocol, M3 morphology, BCR isoform, FLT3-ITD
positive (versus negative), and FLT3-ITD size greater than
60 bp (versus <60 bp and negative together). A WBC count
greater than 10×109/L was the only independent prognos-
tic factor for relapse (P<0.001).
Overall survival
Univariate analysis showed a lower 5-year overall sur-
vival rate in FLT3-ITD-positive patients than in FLT3-ITD-
negative ones (71% versus 81%; P=0.05). In contrast, sim-
ilar 5-year overall survival rates were observed when com-
paring FLT3-D835-positive with FLT3-D835-negative
patients (80% versus 80%; P=0.80) (Tables 3 and 4). 
Multivariate analyses showed that a WBC count greater
than 10×109/L and age over 60 years were independent
prognostic factors for survival (both, P<0.001).
Discussion
This study shows that FLT3-ITD mutations, but not
FLT3-D835 ones, are associated with notable hematologic
and clinical features, such as high WBC counts, high per-
centages of peripheral blood and bone marrow blasts,
coagulopathy, M3v subtype, BCR3 isoform, and expres-
sion of CD2, CD34, HLA-DR, and CD11b surface anti-
gens. Although univariate analyses showed higher induc-
tion death and lower relapse-free survival rates among
FLT3-ITD-positive patients, multivariate analyses revealed
that the FLT3-ITD had no independent prognostic value in
patients with APL treated with ATRA and anthracycline-
based chemotherapy.
As far as we know, our study represents the largest sin-
gle series addressing the clinical significance of FLT3muta-
tions in APL. It should be noted that, although patients
came from 53 institutions, the FLT3 analyses were per-
formed in a limited number of reference laboratories.
Since not all centers performed the FLT3 analyses, which
were not compulsory in the initial diagnostic set, we can-
not definitely exclude a selection bias. Activating muta-
tions of FLT3 have been reported in APL at frequencies
within the range of 12% to 39% for FLT3-ITD (median
21%),5-15,17,33,34 and 6% to 22% for FLT3-D835 (median
9%).6-12,14,15,17 The incidence of these mutations in our
Table 1. Disease and patients’ characteristics according to FLT3-ITD mutations.
FLT3-ITD positive FLT3-ITD negative
Characteristic Median N. (%) Median N. (%) P
(range) (range)
Overall 68 (100) 238 (100) 
PETHEMA trial
LPA96 15 (22) 42 (18) 0.41
LPA99 53 (78) 196 (82)
Age, years 40 (6-72) 41 (2-81)
≤ 18 5 (7) 23 (10) 0.81
19-40 31 (46) 89 (37)
41-60 21 (31) 81 (34)
> 60 11 (16) 45 (19)
Gender
Male 34 (50) 121 (51) 0.91
Female 34 (50) 117 (49)
ECOG score (n=284) 1 (0-3) 1 (0-3)
0-1 45 (78) 173 (71) 0.26
2-3 18 (22) 48 (29)
Fever (n=305)
No 33 (49) 155 (65) 0.02
Yes 34 (51) 83 (35)
Hemorrhage 
No 5 (7) 45 (19) 0.04
Yes 63 (93) 193 (81)
Hepatosplenomegaly (n=299)
No 58 (88) 218 (94) 0.13
Yes 8 (12) 15 (6)
WBC count,×109/L 16.9 (0.6-148) 1.2 (0.2-133) <0.001*
≤ 5 16 (23) 176 (74) <0.001
5-10 8 (12) 20 (8)
10-50 32 (47) 35 (15)
> 50 12 (18) 7 (3)
Relapse-risk group
Low 5 (7) 52 (22) <0.001
Intermediate 19 (28) 144 (60)
High 44 (65) 52 (18)
Blasts in PB, % (n = 276) 82 (0-98) 32 (0-100)
≤ 70 22 (34) 160 (76) <0.001
> 70 42 (66) 52 (24)
Blasts in BM, % (n = 287) 90 (30-100) 89 (6-100)
≤ 70 6 (10) 48 (21) 0.03
> 70 57 (90) 176 (79)
Coagulopathy 
No 9 (13) 66 (28) 0.02
Yes 59 (87) 172 (72)
LDH, IU/L (n = 297) 778 (225-2904) 505 (206-3950)
≤ 600 21 (32) 121 (48) 0.005
> 600 44 (68) 111 (52)
Morphological subtype
Hypergranular 39 (57) 210 (88) <0.001
Microgranular 29 (43) 28 (12)
Cytogenetics (n = 223)
t (15;17) 32 (73) 124 (69) 0.65
t (15;17) plus other** 12 (27) 55 (31)
PML/RARα isoform (n = 298)
BCR1/BCR2 13 (19) 158 (68) <0.001
BCR3 54 (81) 73 (32)
CD2 (n = 201)
Positive 20 (44) 26 (17) < 0.001
Negative 25 (56) 130 (83)
continued in the next column 
continued from the previous column
CD11b (n = 164)
Positive 0 (0) 19 (15) 0.04
Negative 33 (100) 112 (85)
CD34 (n = 233)
Positive 29 (45) 26 (86) <0.001
Negative 24 (55) 154 (14)
HLA-DR (n = 215)
Positive 6 (3) 5 (12) 0.03
Negative 43 (97) 161 (88)
*P compares continuous variables (mean WBC count 28.4 versus 7.4); **plus other additional
chromosomal abnormalities; PB: peripheral blood; BM: bone marrow; LDH: lactate dehydroge-
nase.
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study, 22% and 9%, respectively, are consistent with the
reported data. As in previous studies,9,11,12,14 in our series
the simultaneous presence of both FLT3-ITD and FLT3-
D835 mutations was extremely rare. 
The mutant allelic ratio of FLT3-ITD in APL has been
analyzed in two studies in which median ratios of 1.0
(range, 0.11 to 6.55),11 and 0.66 (range, 0.3 to 1.0),17 were
found in 30 and 19 patients, respectively. In our series of
39 patients for whom the mutant allelic ratio was known,
the median was 0.66 (range, 0.06 to 1.3) which was the
same as that reported by Chillón et al.17 Unlike in the study
by Xue et al.,11 patients with a ratio greater than 2, indicat-
ing loss of wild-type allele, were not observed. 
In line with previous studies,5-7.9,11-15 we found a strong
association between ITD and high WBC counts. We also
found a clear correlation between ITD and M3v and
BCR3, as has previously been reported by others.6-10,12,15
However, the relationship found between ITD and CD34,
CD2, and HLA-DR expression had not been previously
noted. This relationship could be explained by the associ-
ation of the ITD with M3v and BCR3 APL which, in turn,
have been shown to express the CD34, CD2, and HLA-
DR surface markers more frequently.35,36 We confirm that
high WBC counts, like elevated lactate dehydrogenase lev-
els and coagulopathy, are more frequent in FLT3-ITD-
positive APL.5 The increased frequency of hemorrhage
and high percentages of peripheral blood and bone mar-
row blasts that we report here have not been described
previously. In contrast to Xue et al.,11 and Gale et al.,12 we
were unable to show an association between FLT3-D835
and elevated WBC counts or any other clinical or biologi-
cal characteristic. 
As previously reported,11,13,14,33 patients with ITD had an
increased risk of induction death also in our study.
However, the multivariate analysis made clear that this
was due to the association with hyperleukocytosis, a well-
established risk factor for induction death.22 One study sug-
gested that there is an inverse relationship between molec-
ular remission rate and ITD in patients treated with arsenic
trioxide.15 An association between FLT3-ITD and molecu-
Table 2. Disease and patients’ characteristics according to FLT3-D835 muta-
tions.
FLT3-D835 positive FLT3-D835 negative
Characteristic Median N. (%) Median N. (%) P
(range) (range)
Overall 20 (100) 193 (100)
PETHEMA trial
LPA96 3 (15) 39 (20) 0.79
LPA99 17 (85) 154 (80)
Age, years 34 (8-71) 41 (2-81)
≤ 18 4 (20) 15 (8) 0.35
19-40 9 (45) 84 (44)
41-60 5 (25) 55 (28)
> 60 2 (10) 39 (20)
Gender
Male 9 (45) 99 (51) 0.59
Female 11 (55) 94 (49)
ECOG score (n=194) 1 (0-2) 1 (0-3)
0-1 12 (80) 140 (78) 0.99
2-3 3 (20) 39 (22)
WBC count, ×109/L 4.7 (0.6-40) 2.6 (0.3-118) 0.25*
≤ 5 10 (50) 120 (62) 0.29
5-10 3 (15) 19 (10)
10-50 7 (35) 41 (21)
> 50 0 (0) 13 (7)
Relapse-risk group
Low 3 (15) 36 (19) 0.79
Intermediate 10 (50) 103 (53)
High 7 (35) 54 (28)
Blasts in PB, % (n = 192) 73 (0-100) 46 (0-100)
≤ 70 8 (44) 120 (69) 0.07
> 70 10 (56) 54 (31)
Blasts in BM, % (n = 201) 89 (59-100) 89 (7-100)
≤ 70 3 (16) 32 (18) 0.85
> 70 16 (84) 150 (82)
Morphological subtype
Hypergranular 14 (70) 154 (80) 0.46
Microgranular 6 (30) 39 (20)
PML/RARα isoform (n = 205)
BCR1/BCR2 12 (60) 104 (56) 0.75
BCR3 8 (40) 81 (44)
*P compares continuous variables (mean WBC count 10.2 versus 11.8); PB: peripheral blood;
BM: bone marrow.
Table 3. Treatment results according to FLT3-ITD mutations in the study popu-
lation.
FLT3-ITD negative FLT3-ITD positive
N. % N. % P value
of patients of patients
Overall 238 100 68 100
Induction outcome
Complete remission 220* 92 57 84 0.06
Induction death 16 7 11 16 0.03
Positive PCR after induction** 111 56 28 56 0.97
(n=249)
Differentiation syndrome
Severe 30 13 15 22 0.05
Moderate/absent 208 87 53 78
Post-remission outcomes at 5 years
Overall survival  81 71 0.05
Relapse-free survival 88 77 0.02
ITD size > 60 bp. (n=7) NA 57 0.61
ITD size < 60 bp. (n=24) NA 71
ITD ratio > 0.66 (n=16 ) NA 63 0.74
ITD ratio ≤ 0.66 (n=15 ) NA 73
*Two patients among the FLT3-ITD negative cohort were considered as resistant; **Positive PCR
of PML/RARA in a bone marrow sample after induction; NA: Not applicable.
Table 4. Treatment results according to FLT3-D835 mutations in the study pop-
ulation.
FLT3-D835 negative FLT3-D835 positive
N. % N. % P value
of patients of patients
Overall 193 100 20 100
Induction outcome
Complete remission 176* 91 15* 75 0.06
Induction death 16 8 4 20 0.19
Differentiation syndrome
Severe 33 17 2 10 0.62
Moderate/absent 160 83 18 90
Post-remission outcomes at 5 years
Relapse-free survival 84 93 0.29
Overall survival  80 80 0.80
*Two patients were considered as having resistant disease (1 among the FLT3-D835 negative
cohort and 1 among the positive cohort).
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lar remissions was not apparent in the present study.
The associations reported between ITD and overall sur-
vival and relapse-free survival rates have previously been
established by univariate but not by multivariate analy-
sis.9,17,37 In our study, FLT3-ITD status was removed from
the regression equation when WBC count was included in
the multivariate analysis, showing that the adverse long-
term outcome of FLT3-ITD mutations is attributable to its
relationship with elevated WBC count. Furthermore, in a
much larger series, we were unable to demonstrate the
adverse prognostic impact of the ratio and length of FLT3-
ITD mutations reported by Chillón et al.17 We should,
however, be very cautious when interpreting the potential
prognostic impact of the ratio and size of FLT3-ITD muta-
tions because of the low number of datasets available.
Regarding the FLT3-D835, unlike Gale et al.,12 we found no
prognostic significance of this mutation in our series. 
In conclusion, FLT3-ITD mutations, but not FLT3-D835
ones, are associated with characteristic diagnostic hema-
tologic features of APL, in particular with high WBC
counts. However, in a large series of APL patients treated
with ATRA and anthracycline-based chemotherapy, we
were unable to demonstrate an independent prognostic
value of FLT3 mutations. Given the relationship between
FLT3-ITD and high WBC count, targeted therapy with
FLT3 inhibitors could be an attractive strategy to improve
long-term outcome in high-risk patients.12 
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Figure 1. Relapse-free survival in APL patients according to FLT3-
ITD mutation status.
Figure 2. Relapse-free survival in FLT3-ITD positive APL patients
according to ITD size.
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